Behandeling van huidafwijkingen bij doelgerichte medicijnen in de oncologie

Translated title of the contribution: Treatment of skin toxicities with targeted agents in oncology

E. Van Dalen, A. Galimont-Collen, J. J. Koldenhof, S. H. Kardaun, M. T. Bousema, M. M.D. Van Der Linden, C. Van Montfrans*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


In recent years new targeted agents have been developed for the treatment of malignancies, including inhibitors of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (receptor) (VEGF(R)), mammaliantarget of rapamycin (mTOR) and BRAF. These inhibitors frequently cause skin toxicity. Treatment of skin toxicity is important to ensure continued treatment with the targeted agent and improve quality of life. However, there are no 'evidence based guidelines' for treatment of the skin toxicity. In this article we provide an overview of the recent literature, a description of the most common adverse effects of the skin, hairs, nails and eyes and the therapeutic options to best treat these adverse events.

Translated title of the contributionTreatment of skin toxicities with targeted agents in oncology
Original languageDutch
Pages (from-to)289-298
Number of pages10
JournalNederlands Tijdschrift voor Dermatologie en Venereologie
Issue number5
Publication statusPublished - 2012


  • BRAF
  • EGFR
  • MTOR
  • Skin toxicity
  • Targeted agents
  • VEGF(R)


Dive into the research topics of 'Treatment of skin toxicities with targeted agents in oncology'. Together they form a unique fingerprint.

Cite this